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Article category: Epidemiology 
 
Brief description of the novelty and impact of the work: The association of Se status with 
CRC development is controversial. The present study shows that Se status is suboptimal for 
SePP saturation in many Western Europeans and that a higher Se status is inversely 
associated with CRC risk, which is more evident in women. The contrasting results of our 
study and those from the NPC and SELECT Se intervention trials may be due to differences 
in baseline Se levels of study participants. In populations where Se status is sub-optimal 
(e.g. Western Europe) increasing Se intake may reduce CRC risk. 
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ABSTRACT   
Suboptimal intakes of the micronutrient selenium (Se) are found in many parts of Europe. 
Low Se status may contribute to colorectal cancer (CRC) development. We assessed Se 
status by measuring serum levels of Se and Selenoprotein P (SePP) and examined the 
association with CRC risk in a nested case-control design (966 CRC cases; 966 matched 
controls) within the European Prospective Investigation into Cancer and Nutrition. Se was 
measured by total reflection X-ray fluorescence and SePP by immunoluminometric sandwich 
assay. Multivariable incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were 
calculated using conditional logistic regression. Respective mean Se and SePP levels were 
84.0 µg/L and 4.3 mg/L in cases and 85.6 µg/L and 4.4 mg/L in controls. Higher Se 
concentrations were associated with a non-significant lower CRC risk (IRR = 0.92, 95%CI: 
0.82-1.03 per 25 µg/L increase). However, sub-group analyses by sex showed a statistically 
significant association for women (Ptrend = 0.032; per 25 µg/L Se increase, IRR = 0.83, 
95%CI: 0.70-0.97) but not for men. Higher SePP concentrations were inversely associated 
with CRC risk (Ptrend = 0.009; per 0.806 mg/L increase, IRR = 0.89, 95%CI: 0.82-0.98) with 
the association more apparent in women (Ptrend = 0.004; IRR = 0.82, 95%CI: 0.72-0.94 per 
0.806 mg/L increase) than men (Ptrend = 0.485; IRR = 0.98, 95%CI: 0.86-1.12 per 0.806 
mg/L increase). The findings indicate that Se status is suboptimal in many Europeans and 
suggest an inverse association between CRC risk and higher serum Se status, which is more 
evident in women. 
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INTRODUCTION 
 
In Europe, colorectal cancer (CRC) is the second leading cause of cancer related 
death1. Varying international CRC incidence rates and observations from migrant studies 
have long suggested that modifiable factors such as diet and lifestyle play an important role 
in CRC aetiology, however there is little knowledge on how dietary micronutrients affect 
disease risk2. 
Selenium (Se) is an essential micronutrient for human health whose biological 
activities and potential anti-carcinogenic properties likely result from its incorporation as the 
amino acid selenocysteine in selenoproteins encoded by 25 separate human genes with 
roles in cell protection from oxidative stress, redox control and the inflammatory response3, 
4. Due to differing soil Se levels and resultant food content, there is great geographical 
variation in dietary Se intake worldwide5. As a result the Se status of many populations, 
including those across Europe is low compared with much of North America5, 6. Such 
relatively low intake has been associated with an increased risk of a number of major 
diseases7, 8 .  
 
There is much current debate as to whether Se influences development of CRC or its 
precursor colorectal adenoma (CRA) lesions. A recent randomized trial supplementing 
antioxidant nutrients including Se showed a significant protective effect on CRA recurrence9. 
Three other analyses based on subjects enrolled in randomized CRA prevention trials with Se 
alone have also considered the association of baseline Se levels and CRA recurrence. The 
first did not indicate any association10, the second observed a significant inverse 
association11, while the third observed a reduced risk in smokers only12. Data from the 
Nutritional Prevention of Cancer (NPC) intervention trial13, 14 and case-control and cohort 
studies (see15, 16 for reviews) suggest that a low Se intake is associated with a higher CRC 
risk. However, a subsequent intervention trial among men (Selenium and Vitamin E Cancer 
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Prevention Trial, SELECT)17 and a prospective cohort among women (Women’s Health 
Initiative, WHI)18 have shown no associations. In the NPC study, Se supplementation had a 
significant effect on CRC risk in volunteers with a baseline plasma Se of <106 µg/L whereas 
the SELECT trial and the WHI prospective study included too few participants with levels 
within this range. 
 
Differences in the range of Se or baseline Se status between these studies19 and 
differences in risk of CRC by sex12, 18, 20 are major possible explanations for these discrepant 
findings. Overall, these studies suggest that an association with cancer risk is more likely for 
individuals in populations with lower Se levels (possibly due to a lower Se availability5, 6). 
Effect modification by sex appears to be biologically plausible due to differences in 
metabolism, excretion, and interaction between Se and other factors (e.g., alcohol and 
smoking)21-24.  
 
However, there is no strong epidemiologic evidence available for the association of 
Se status with CRC risk in European populations. Existing data are compromised by the lack 
of robust markers of Se status and / or studies with small sample sizes15, 19. Selenoprotein P 
(SePP) is regarded as the best biomarker of functional Se as serum SePP protein is the 
major transporter of hepatic Se towards other tissues and reflects long-term intake that is 
less influenced by the chemical form of the ingested Se25. Nevertheless, the association of 
circulating SePP protein levels with CRC risk has not previously been studied in European 
populations.   
 
We hypothesized that a low Se status is associated with a higher CRC risk and that 
the influence of Se status on CRC risk is modulated by sex. In this study, we evaluated the 
association between pre-diagnostic Se and SePP concentrations in serum and CRC risk in 
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samples taken from 966 CRC cases and 966 matched controls nested within the large, 
European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. 
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MATERIALS AND METHODS  
Study population and data collection 
EPIC is a multicentre prospective cohort study designed to investigate the 
associations between diet, lifestyle, genetic and environmental factors and various types of 
cancer. The rationale and methods of the EPIC design have been published previously26, 27. 
In summary, 521,448 participants (aged 25-70 years; approximately 70% women) were 
enrolled between 1992-2000 in 23 sub-cohorts in 10 European countries (Denmark, France, 
Germany, Greece, Italy, the Netherlands, Norway, Spain, Sweden, and United Kingdom). 
The present analysis is based on participant data from all centres except for Norway (blood 
samples only recently collected; few CRCs diagnosed after blood donation) and Sweden (no 
available serum samples). Detailed and validated dietary (country-specific questionnaires) 
and lifestyle data (standardized questionnaires), anthropometrics, and biological samples 
were collected at the time of enrolment. Serum samples are stored at the International 
Agency for Research on Cancer (IARC) at -196°C under liquid nitrogen for all countries 
except Denmark (-150°C, nitrogen vapour). Written informed consent was provided by all 
study participants. Ethical approval for the EPIC study was obtained from the review boards 
of the IARC and local participating centres. 
Incident cancer cases were identified by follow-up based on population cancer 
registries (Denmark, Italy, Netherlands, Spain, United Kingdom) and other methods such as 
health insurance records, pathology registries and active contact of study subjects or next of 
kin (France, Germany, Greece). Complete follow-up censoring dates varied amongst centres, 
ranging between June 2002 and June 2003. 
 
Selection of cases and control subjects 
Case subjects were men and women who developed first incident, histologically-
confirmed CRC after recruitment and latest follow-up date. Cancer incidence data were 
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coded using the 10th Revision of the International Classification of Diseases (ICD-10) and 
the second revision of the International Classification of Disease for Oncology (ICDO-2). 
Colon cancers were defined as tumours in the cecum, appendix, ascending colon, hepatic 
flexure, transverse colon, splenic flexure, descending and sigmoid colon (C18.0-C18.7), and 
overlapping or unspecified origin tumours (C18.8 and C18.9). Rectal cancers were defined 
as tumours occurring at the recto-sigmoid junction (C19) or rectum (C20). Anal canal 
cancers (C21) were excluded. Colorectal cancer is the combination of the colon and rectal 
cancer cases. 
 
All subjects with prior cancer diagnoses at any site (except non-melanoma skin 
cancer) or with missing values on any Se status biomarkers were excluded. The total 
number of samples processed for Se and SePP measurements in the laboratory was 2192 
(cases=1096, controls=1096), from which 130 case-control sets had missing biomarker 
measurements in either the case or matched control, due to insufficient availability of bio-
sample for laboratory analysis, so that 1932 individuals (cases=966, controls=966) were 
included in the final dataset and utilized in the present analyses. Cases were matched 1:1 by 
study centre of enrolment, sex, age at blood collection time of blood collection and fasting 
status and among women, menopausal status. Premenopausal women were matched on 
phase of menstrual cycle and postmenopausal women were matched on current hormonal 
replacement therapy (HRT) use.  
 
Serum selenium and SePP measurements  
Total Se levels were measured from 20 µl of each blood serum sample by X-ray 
fluorescence, using a bench-top total reflection X-ray fluorescence (TXRF) spectrometer 
(PicofoxTM S2, Bruker Nano GmbH, Berlin, Germany) as described previously28. 
Concentrations of the SePP protein were measured from 20 µl of each blood serum sample 
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by an immunoluminometric sandwich assay29 (Selenotest™, ICI GmbH, Berlin, Germany) 
essentially as described previously30. For quality-control, case-control status was blinded and 
two serum samples of known Se and SePP concentrations for intra-assay variability were 
used in each analysis plate. Se measurements were controlled with a commercial standard 
serum (Seronorm, Billingstad, Norway) and an atomic absorption standard (1000 mg/ml, 
Sigma, Taufkirchen, Germany). The samples were measured in duplicate and the mean 
concentration values, standard deviation and coefficient of variation were calculated. 
Duplicate samples with differences in concentration varying by more than 10% were 
measured again. The evaluation was performed using GraphPad Prism 6.01 (La Jolla, CA, 
USA) using a 4-parameter logistic function (4PL). The coefficient of variation was 7.3% and 
7.2% for controls 1 (SePP: 1.5 mg/L) and 2 (SePP: 8.6 mg/L), respectively.  
 
Statistical Analysis  
Serum Se and SePP concentrations were compared by linear Pearson product-
moment correlation. Analysis of covariance (values were natural logarithm transformed to 
approximate a normal distribution) was used to examine geometric mean differences in Se 
and SePP concentrations among the controls by baseline characteristics, with adjustment for 
study centre. P-values for tests of trend (for ordinal variables) or of heterogeneity were 
reported. 
 
Two conditional logistic models, 1) with matching factors only, and 2) with 
adjustment for a priori selected confounders including smoking status/duration/intensity, 
physical activity (combined recreational and household activity; expressed as sex-specific 
categories of metabolic equivalents), education level, and continuous measures for body 
mass index (BMI; kg/m2), total dietary energy consumption (kcal/d), and intakes of alcohol 
(g/d), calcium (g/d), fruits and vegetables (g/d), and red and processed meats (g/d) were 
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used to assess the strengths of association [incidence rate ratio (IRR) as estimated by odds 
ratio (OR)31 with 95% confidence interval (CI) and tests for trend]. Adjustments for dietary 
fibre intake (instead of fruits and vegetables), and consumption of fish (in addition to and 
instead of red and processed meats) did not change the effect estimates. Se and SePP 
concentrations were included in models as continuous [per 25 µg/L and 0.806 mg/L, 
respectively; approximately 1 standard deviation (SD)] and as categorical variables, with 
quintile cut-points based on the distribution in the control subjects. All analyses were run 
separately for CRC and by anatomical sub-sites of colon and rectum, and for men and 
women separately and combined using the same categorical cut-points for all tests. To test 
dose-responses, trend variables were assigned the median values for Se or SePP quintiles 
and predefined categories. Heterogeneity of effects by sex and anatomical sub-site were 
assessed by χ2 statistic. 
 
Effect modification on the multiplicative scale for potential biologically plausible effect 
modifying variables (age at diagnosis, BMI, smoking, baseline alcohol consumption; and 
among women, menopausal status and HRT use) was tested by including interaction terms 
formed by the product of modifying variable categories and the value of categories of 
exposure of interest. The statistical significance of interactions was assessed using likelihood 
ratio tests based on the models with and without the interaction terms. In sensitivity 
analyses, analyses were limited to follow-up of >2 years after blood collection to assess 
possible reverse causation. 
 
All statistical tests were two-sided, and P-values<0.05 were considered statistically 
significant. Analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC) 
statistical package.  
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RESULTS 
Baseline Characteristics of Participants 
The baseline characteristics of participants are presented in Table 1. Colon and 
rectal cancer cases were diagnosed, on average, 3.7 and 3.9 years after blood collection, 
respectively. Cases were more likely to be current smokers, to have higher intakes of alcohol 
and red and processed meats per day, and were less likely to be physically active. Serum 
concentrations of SePP and Se correlate significantly among the participants (r = 0.60; P = 
<0.001). No statistically significant differences by case-control status in serum Se were 
detected (PCRC =0.147; Pcolon = 0.097; Prectum = 0.816). Geometric mean serum SePP was 
lower in CRC cases vs. controls (4.2 vs. 4.3 mg/L; P = 0.027), and particularly in colon 
cancer cases vs. controls (4.1 vs. 4.3 mg/L; P = 0.008), but not in rectal cancer cases (4.2 
vs. 4.3 mg/L; P = 0.922). 
 
Selenium and SePP levels by Baseline Characteristics among Controls 
Concentrations of Se and SePP did not differ statistically significantly by sex (see 
Table 2; P for Se = 0.079, P for SePP = 0.674). The mean serum Se and SePP 
concentrations varied significantly between countries and Western European geographic 
regions (grouped as Northern, Central or Southern; P < 0.001). Comparisons by country are 
compromised due to the small participant numbers in France and Greece. Considering the 
regional groupings the order of highest to lowest concentrations of both Se and SePP was 
Northern (represented by Denmark) > Southern (France, Italy, Spain, Greece) > Central 
(UK, the Netherlands, Germany) areas. Serum levels of Se differ by smoking status in men 
(P = 0.041), with the lowest values in current smokers. In men and in women, higher 
consumption of total fish and shellfish was statistically significantly associated with higher 
concentrations of SePP (Pmen = 0.021; Pwomen = 0.051). Among women, higher total fruits 
and vegetables intake was positively associated with SePP (P = 0.017); whereas in men, 
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higher intake of red and processed meat was associated with higher concentrations of SePP 
(P = 0.011). No statistically significant differences were found between BMI, age, physical 
activity, alcohol intake and serum Se or SePP concentrations (Table 2). 
 
Selenium Concentrations and CRC risk  
The association between serum Se concentration and CRC risk is shown in Table 3.  
A higher Se concentration was not statistically significantly associated with an altered CRC 
risk in all participants (multivariable IRRQ5 vs. Q1 = 0.88, 95% CI: 0.64 – 1.21 for the fifth 
quintile versus the first quintile, Ptrend =0.458; IRR = 0.92, 95% CI: 0.82-1.03 per 25 µg/L 
increase in Se concentration). Similarly, there were no notable effects of Se level when 
assessing the major anatomical sub-site classification of cancers located in the colon or 
rectum. Among men, serum Se concentration was not associated with CRC risk overall, or by 
anatomical sub-site. However, among women, participants in the highest quintile had a 36% 
lower risk of CRC that did those in the lowest quintile (Ptrend = 0.032;  per 25 µg/L, IRR = 
0.83, 95% CI: 0.70-0.97; Pheterogeneity by sex = 0.105), and a similar reduction in risk was found 
by anatomical sub-site (for colon Ptrend = 0.045; per 25 ug/L, IRR = 0.84, 95% CI: 0.68-
1.05; for rectum Ptrend = 0.271; per 25 µg/L, IRR = 0.74, 95% CI: 0.57-0.98;  Pheterogeneity by 
sub-site = 0.474). 
 
SePP Concentrations and CRC risk 
The association of serum SePP concentration and CRC risk is shown in Table 4. 
Higher serum SePP level was associated with a statistically significant lower risk of CRC in all 
participants (multivariable IRRQ5 vs. Q1 = 0.60, 95% CI = 0.42-0.85; Ptrend=0.009). There was 
a significant 11% reduction in CRC risk per 0.806 mg/L serum SePP increase (IRR = 0.89, 
95% CI = 0.82-0.98). To further understand components involved in this association, we 
sub-divided our study according to anatomical sub-sites and sex. In the analysis by colon 
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sub-site, the association of SePP with disease risk was statistically significant in colon 
cancers (Ptrend = 0.003; per 0.806 mg/L, IRR = 0.85, 95% CI = 0.75-0.95) but not in rectal 
cancers (Ptrend = 0.806; per 0.806 mg/L, IRR = 0.96, 95% CI = 0.82-1.13; Pheterogeneity by sub-site 
= 0.231). Among men, serum SePP concentration was not associated with CRC risk 
(Ptrend=0.485; per 0.806 mg/L, IRR = 0.98, 95% CI: 0.86-1.12). Among women, higher 
SePP level was associated with a statistically significant lower risk of CRC (multivariable IRR 
Q5 vs. Q1 = 0.46, 95% CI: 0.28-0.78, Ptrend=0.004; per 0.806 mg/L, IRR = 0.82, 95% CI: 0.72-
0.94; Pheterogeneity by sex = 0.230). The associations with SePP status for women were highly 
significant for cancers of the colon (Ptrend = 0.008; per 0.806 mg/L, IRR = 0.82, 95% CI: 
0.62-0.96) but not rectum (Ptrend = 0.386; per 0.806 mg/L, IRR = 0.82, 95% CI: 0.63-1.08; 
Pheterogeneity by sub-site = 0.710).  
 
Interaction and Sensitivity Analyses 
The results did not differ by sex and colon site (All P-values for heterogeneity 
>0.11).  No multiplicative interactions were statistically significant (all P-values were ≥0.06). 
Selected results for age at blood collection, BMI and smoking status per 25 µg/L increase in 
Se and SePP are shown in Supplemental Table 1. The exclusion of cases with less than 
two years of follow-up did not change any of the results (data not shown). 
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DISCUSSION 
The results of this study represent the largest prospective analysis of the association 
of serum Se status biomarkers (total serum Se levels and SePP protein concentrations) with 
risk of CRC in European populations. Our findings indicate that higher levels of serum Se are 
significantly associated with a lower CRC risk in women only and that higher concentrations 
of SePP, a functional biomarker of Se status, are significantly associated with a lower CRC 
risk. This suggests that Se intake/status is an important factor in affecting CRC risk in a 
population of marginally low Se status, such as in Europe5, 6. 
 
 Previous work from two major Se intervention trials in North America provides 
conflicting results with regards to Se intake and CRC risk. Differences in baseline Se levels of 
the participants may be the crucial factor in explaining this, while other important issues 
may include sex-specific CRC risks, the type of Se supplementation utilized and that CRC 
was only a secondary endpoint in both the NPC and SELECT studies (so that there was low 
power to see an effect of intervention for this cancer site)19. In the NPC trial13, a decreased 
CRC incidence was only observed in participants with a baseline plasma Se level of <106 
µg/L. In the SELECT trial17, which did not show a significant cancer chemoprevention effect 
of Se supplementation, the baseline serum Se levels ranged from 122 to 152 µg/L (mean 
136 µg/L) which has been shown to ensure optimal glutathione peroxidase 3 (GPx3) 
expression and SePP saturation32-34. A comparable range of blood serum Se concentration 
was reported in the WHI prospective study (111 - 162 µg/L; mean 134 µg/L), which also 
showed no association between Se concentration and CRC risk18. Recently, the large 
National Health and Nutrition Examination Survey (NHANES) III survey of over 16,000 adults 
in the United States reported a range of blood serum Se from 109 – 136 µg/L (mean 125 
µg/L) along with an inverse association between all-cancer mortality and Se at levels above 
126 µg/L35. Notably, all these studies had baseline Se levels comparable to the highest 
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quintile of our study (>101 µg/L) suggesting that the effects of Se on CRC risk may be 
negated if the baseline range is above this and at levels known to saturate selenoprotein 
biosynthesis, based on our current knowledge of those selenoproteins such as SePP and 
GPx3 that can be measured in humans (there is little known about saturation requirements 
of intracellular selenoproteins). 
 As serum SePP concentrations become maximally saturated when Se intake and 
Se status are replete, SePP is a particularly relevant biomarker for Se status assessment in 
subjects with Se deficient to borderline levels36. The estimated cut-off for Se sufficiency 
ensuring maximal expression of SePP is a blood Se concentration (ascertained in plasma) of 
90–124 µg/L33, 34. Approximately 95% of the EPIC subjects had serum Se levels below <124 
µg/L (and approximately 80% were below 100 µg/L). The correlation between Se and SePP 
levels was relatively high (r = 0.60; P = <0.001), indicating that most subjects were sub-
optimal in Se when judged by previously published data on Se levels required for full 
expression of SePP and other selenoproteins as the criterion for Se sufficiency22, 25, 33, 34. This 
contrasts with data from a study of adequately Se supplied healthy individuals in the United 
States where the average plasma Se concentration was 142 µg/L and SePP and Se levels did 
not correlate37, presumably because the surplus Se is present as selenomethionine in other 
serum proteins. Among lifestyle and dietary variables adjusted for in our analyses Se and 
SePP levels differed by smoking status, dietary intake of fish, meat, and fruit and vegetables 
(Table 2) as found for previous studies21, 38, 39.  
 
The association of lower CRC risk with increasing Se and SePP concentrations was 
more apparent for women than for men. The recommended dietary allowances for Se8 are 
generally higher for men based primarily on data from animal studies showing Se 
requirements are higher in males; partly due to body mass and possibly also the 
requirement of Se for sperm production and sperm protection40. However, to date there has 
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been no study in humans showing an increased need for Se in men. Our findings are 
supported by previous studies showing a potential effect of estrogen on Se and 
selenoprotein levels, and a differential response to Se supplementation by sex20, 41-43. 
Additionally, there are clear differences between males and females in regard to Se 
biomarker outcomes22, 24, e.g. urinary Se was higher in women after Se supplementation 
suggesting that men retain Se better than women22, but the reasons for this are not well 
understood. Previously, a GPX4 selenoprotein gene variant was reported to affect 
lymphocyte protein level in females only42, and sex has been shown to influence the 
differential effects of polymorphic variants in the SEPP1 gene (which codes for the SePP 
protein) on plasma SePP44 and associations with particular selenoprotein genetic variants 
and CRC risk45.  
 
However, in contrast, several cohort studies and clinical trials suggest that Se status 
influences cancer risk in men more than women14, 18, 20. Possibly, women are more 
susceptible to the effects of lower Se intakes, which would not have been seen for most of 
these previous studies as their baseline Se levels were too high. Interestingly, significant 
interactions were reported between selenoprotein gene variants and oestrogen status with 
colon and rectal cancer risk46. The authors suggested that although this could possibly be 
due to the anti-inflammatory properties of oestrogen and the influence of oestrogen on the 
tissue distribution and metabolism of Se, as shown in animal models47. We do not see a 
statistically significant interaction of Se and CRC risk by HRT use and colon site among 
women, although we have limited power for this analysis. Differences in dietary factors may 
provide further insight into potential mechanisms of Se-associated colorectal carcinogenesis 
between the sexes. Although none of these factors were significant effect modifiers of the 
association of Se or SePP with CRC risk, it is interesting that SePP concentrations were 
associated with red and processed meat intake in males only and with fish intake in both 
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males and females. It can be speculated that as fish and meat represent a good source of 
Se supply, they could, in that respect, confer some protection against CRC, although for 
men this may be slightly masked by the adverse effects of a high consumption of red and 
processed meat48. 
 
The study strengths include an appreciable sample size within a large, prospective 
study with extensive data on lifestyle and other dietary factors, pre-diagnostic bloods. Use of 
blood samples taken at time points prior to CRC diagnoses and use of prospectively collected 
dietary and lifestyle data minimises recall and reverse causality biases. A second major 
strength lies in the determination of the two most meaningful biomarkers of Se status, i.e., 
total Se and SePP serum concentrations30, 33. The main limitations are the single time-point 
blood measure per subject, giving room for random error, and the relatively short follow-up 
time (~4 years). However, the presence of random error would rather bias the estimates 
towards null and exclusion of cases with less than two years of follow-up did not appreciably 
alter the findings. Despite the large sample size, some stratified analyses had limited power, 
particularly sub-group analyses by sex and anatomical sub-sites. Another potential limitation 
applicable to all observational studies is the possibility of residual confounding. However, in 
our models we adjusted for a large number of potentially relevant confounding variables. 
There was no information on CRC screening. However, in Western Europe there is no 
consistent CRC screening modality and only recently have several national screening 
programs been piloted or implemented, which mainly employ immunochemical faecal occult 
blood testing49.  
 
In conclusion, the present study provides significant prospective data indicating an 
association between high Se status and a lower risk of CRC and that in populations where 
Se status is sub-optimal (e.g. Western Europe) increasing Se intake may reduce risk of CRC, 
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especially for women. An optimum dietary Se level for CRC prevention may vary according 
to life-stage, sex, general state of health, colorectal sub-site, and genotype15. We are 
currently examining the potential modifying effect of common genetic variation in the 
selenoprotein gene pathway on the risk of CRC associated with Se status. An improved 
understanding of how individuals "respond" to Se and how this modifies CRC risk is crucial in 
designing targeted supplementation trials or a public health strategy, as Se supplementation 
is controversial although this requires further study50. Furthermore, as the next major step in 
resolving these issues, the applicability of a Se status biomarker oriented Se 
supplementation trial for CRC prevention needs to be examined in a population with sub-
optimal Se availability.  
 
 
  
Page 21 of 32
John Wiley & Sons, Inc.
International Journal of Cancer
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 
21 
 
Acknowledgements  
Funding for this study was provided by the Health Research Board of Ireland project grants 
HRA_PHS/2011/3 and HRA_PHS/2013/397 (to DJH). The EPIC study was supported by 
“Europe Against Cancer” Programme of the European Commission (SANCO); Ligue contre le 
Cancer; Institut Gustave Roussy; Mutuelle Générale de l’Education Nationale; Institut 
National de la Santé et de la Recherche Médicale (INSERM); German Cancer Aid; German 
Cancer Research Center; German Federal Ministry of Education and Research; Danish 
Cancer Society; Health Research Fund (FIS) of the Spanish Ministry of Health; the CIBER en 
Epidemiología y Salud Pública (CIBERESP), Spain; ISCIII RETIC (RD06/0020); Spanish 
Regional Governments of Andalusia, Asturias, Basque Country, Murcia (No 6236) and 
Navarra and the Catalan Institute of Oncology; Cancer Research UK; Medical Research 
Council, UK; the Hellenic Health Foundation; Italian Association for Research on Cancer; 
Italian National Research Council; Compagnia di San Paolo; Dutch Ministry of Public Health, 
Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch 
Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund 
(WCRF), Statistics Netherlands (The Netherlands); Swedish Cancer Society; Swedish 
Scientific Council; Regional Governments of Skane and Vasterbotten, Sweden; and 
Nordforsk centre of excellence programme HELGA. LS was supported by Deutsche 
Forschungsgemeinschaft (DFG; GraKo 1208, SCHO849/4-1) and Federal Ministry of 
Economics and Technology (BMWi; KF2263202CS2). CM was supported by a grant (to JEH) 
from the Biotechnology and Biological Sciences Research Council, UK (BSSRC; 
BB/H011471/1). DP was supported by the Associazione Italiana per la Ricerca sul Cancro-
AIRC-Italy. We thank Katja Schreiber and Torsten Schulz for help with the Se status 
analyses in the lab of LS. The authors have declared that no competing interests exist.  
 
 
Page 22 of 32
John Wiley & Sons, Inc.
International Journal of Cancer
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 
22 
 
REFERENCES  
 
1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, 
Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 
countries in 2012. Eur J Cancer 2013;49(6):1374-403.  
2. Cappellani A, Zanghi A, Di Vita M, Cavallaro A, Piccolo G, Veroux P, Lo Menzo E, 
Cavallaro V, de Paoli P, Veroux M, Berretta M. Strong correlation between diet and 
development of colorectal cancer. Front Biosci (landmark edition) 2013;18:190-8. 
3. Bellinger FP, Raman AV, Reeves MA, Berry MJ. Regulation and function of 
selenoproteins in human disease. Biochem J 2009;422(1):11-22. 
4. Hatfield DL, Tsuji PA, Carlson BA, Gladyshev VN. Selenium and selenocysteine: roles 
in cancer, health, and development. Trends Biochem Sci 2014;39(3):112-20.  
5. Rayman MP. Food-chain selenium and human health: emphasis on intake. Br J Nutr 
2008;100(2):254-68. 
6. Johnson CC, Fordyce FM, Rayman MP. Symposium on 'Geographical and geological 
influences on nutrition': Factors controlling the distribution of selenium in the environment 
and their impact on health and nutrition. P oc Nutr Soc 2010;69(1):119-32. 
7. Rayman MP. Selenoproteins and human health: insights from epidemiological data. 
Biochim Biophys Acta 2009;1790(11):1533-40. 
8. Fairweather-Tait SJ, Bao Y, Broadley MR, Collings R, Ford D, Hesketh JE, Hurst R. 
Selenium in human health and disease. Antioxid Redox Signal 2011;14(7):1337-83.  
9. Bonelli L, Puntoni M, Gatteschi B, Massa P, Missale G, Munizzi F, Turbino L, Villanacci 
V, De Censi A, Bruzzi P. Antioxidant supplement and long-term reduction of recurrent 
adenomas of the large bowel. A double-blind randomized trial. J Gastroenterol 
2013;48(6):698-705.  
10. Wallace K, Byers T, Morris JS, Cole BF, Greenberg ER, Baron JA, Gudino A, Spate V, 
Karagas MR. Prediagnostic serum selenium concentration and the risk of recurrent colorectal 
adenoma: a nested case-control study. Cancer Epidemiol Biomarkers Prev 2003;12(5):464-
7.  
11. Jacobs ET, Jiang R, Alberts DS, Greenberg ER, Gunter EW, Karagas MR, Lanza E, 
Ratnasinghe L, Reid ME, Schatzkin A, Smith-Warner SA, Wallace K, et al. Selenium and 
colorectal adenoma: results of a pooled analysis. J Natl Cancer Inst 2004;96(22):1669-75. 
Page 23 of 32
John Wiley & Sons, Inc.
International Journal of Cancer
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 
23 
 
12. Peters U, Chatterjee N, Church TR, Mayo C, Sturup S, Foster CB, Schatzkin A, Hayes 
RB. High serum selenium and reduced risk of advanced colorectal adenoma in a colorectal 
cancer early detection program. Cancer Epidemiol Biomarkers Prev 2006;15(2):315-20.  
13. Clark LC, Combs GF, Jr., Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, 
Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL, Jr., et al. Effects of selenium 
supplementation for cancer prevention in patients with carcinoma of the skin. A randomized 
controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996;276(24):1957-63. 
14. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF, Jr., Slate EH, Fischbach LA, 
Marshall JR, Clark LC. Baseline characteristics and the effect of selenium supplementation on 
cancer incidence in a randomized clinical trial: a summary report of the Nutritional 
Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 2002;11(7):630-9. 
15. Meplan C, Hesketh J. The influence of selenium and selenoprotein gene variants on 
colorectal cancer risk. Mutagenesis 2012;27(2):177-86.  
16. Vinceti M, Crespi CM, Malagoli C, Del Giovane C, Krogh V. Friend or foe? The current 
epidemiologic evidence on selenium and human cancer risk. J  Environ Sci Health, Part A 
2013;31(4):305-41.  
17. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, 
Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, 3rd, et al. Effect of selenium 
and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E 
Cancer Prevention Trial (SELECT). JAMA 2009;301(1):39-51. 
18. Takata Y, Kristal AR, King IB, Song X, Diamond AM, Foster CB, Hutter CM, Hsu L, 
Duggan DJ, Langer RD, Petrovitch H, Shikany JM, et al. Serum selenium, genetic variation in 
selenoenzymes, and risk of colorectal cancer: primary analysis from the Women's Health 
Initiative Observational Study and meta-analysis. Cancer Epidemiol Biomarkers Prev 
2011;20(9):1822-30.  
19. Steinbrenner H, Speckmann B, Sies H. Toward understanding success and failures in 
the use of selenium for cancer prevention. Antioxid Redox Signal 2013;19(2):181-91. 
20. Waters DJ, Chiang EC, Cooley DM, Morris JS. Making sense of sex and supplements: 
differences in the anticarcinogenic effects of selenium in men and women. Mutat Res 
2004;551(1-2):91-107.  
21. Combs GF, Jr. Selenium in global food systems. Br J Nutr 2001;85(5):517-47.  
22. Combs GF, Jr., Jackson MI, Watts JC, Johnson LK, Zeng H, Idso J, Schomburg L, 
Hoeg A, Hoefig CS, Chiang EC, Waters DJ, Davis CD, et al. Differential responses to 
selenomethionine supplementation by sex and genotype in healthy adults. Br J Nutr 
2012;107(10):1514-25.  
Page 24 of 32
John Wiley & Sons, Inc.
International Journal of Cancer
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 
24 
 
23. Riese C, Michaelis M, Mentrup B, Gotz F, Kohrle J, Schweizer U, Schomburg L. 
Selenium-dependent pre- and posttranscriptional mechanisms are responsible for sexual 
dimorphic expression of selenoproteins in murine tissues. Endocrinology 2006;147(12):5883-
92.  
24. Schomburg L, Schweizer U. Hierarchical regulation of selenoprotein expression and 
sex-specific effects of selenium. Biochim Biophys Acta 2009;1790(11):1453-62.  
25. Ashton K, Hooper L, Harvey LJ, Hurst R, Casgrain A, Fairweather-Tait SJ. Methods of 
assessment of selenium status in humans: a systematic review. Am J Clin Nutr 
2009;89(6):2025S-39S. 
26. Riboli E, Kaaks R. The EPIC Project: rationale and study design. European 
Prospective Investigation into Cancer and Nutrition. Int J Epidemiol 1997;26 Suppl 1:S6-14. 
27. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, Charrondiere UR, Hemon B, 
Casagrande C, Vignat J, Overvad K, Tjonneland A, et al. European Prospective Investigation 
into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 
2002;5(6B):1113-24. 
28. Hoeflich J, Hollenbach B, Behrends T, Hoeg A, Stosnach H, Schomburg L. The choice 
of biomarkers determines the selenium status in young German vegans and vegetarians. Br 
J Nutr 2010;104(11):1601-4.  
29. Hollenbach B, Morgenthaler NG, Struck J, Alonso C, Bergmann A, Kohrle J, 
Schomburg L. New assay for the measurement of selenoprotein P as a sepsis biomarker 
from serum. J Trace Elem Med Biol 2008;22(1):24-32. 
30. Steinbrecher A, Meplan C, Hesketh J, Schomburg L, Endermann T, Jansen E, 
Akesson B, Rohrmann S, Linseisen J. Effects of selenium status and polymorphisms in 
selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer 
Epidemiol Biomarkers Prev 2010;19(11):2958-68.  
31. Knol MJ, Vandenbroucke JP, Scott P, Egger M. What do case-control studies 
estimate? Survey of methods and assumptions in published case-control research. Am J 
Epidemiol 2008;168(9):1073-81.  
32. Burk RF, Hill KE. Selenoprotein P: an extracellular protein with unique physical 
characteristics and a role in selenium homeostasis. Annu Rev Nutr 2005;25:215-35. 
33. Hurst R, Armah CN, Dainty JR, Hart DJ, Teucher B, Goldson AJ, Broadley MR, Motley 
AK, Fairweather-Tait SJ. Establishing optimal selenium status: results of a randomized, 
double-blind, placebo-controlled trial. Am J Clin Nutr 2010;91(4):923-31.  
34. Xia Y, Hill KE, Li P, Xu J, Zhou D, Motley AK, Wang L, Byrne DW, Burk RF. 
Optimization of selenoprotein P and other plasma selenium biomarkers for the assessment 
Page 25 of 32
John Wiley & Sons, Inc.
International Journal of Cancer
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 
25 
 
of the selenium nutritional requirement: a placebo-controlled, double-blind study of 
selenomethionine supplementation in selenium-deficient Chinese subjects. Am J Clin Nutr 
2010;92(3):525-31. 
35. Goyal A, Terry MB, Siegel AB. Serum Antioxidant Nutrients, Vitamin A, and Mortality 
in U.S. Adults. Cancer Epidemiol Biomarkers Prev 2013. 
36. Schomburg L, Kohrle J. On the importance of selenium and iodine metabolism for 
thyroid hormone biosynthesis and human health. Mol Nutr Food Res 2008;52(11):1235-46. 
37. Combs GF, Jr., Watts JC, Jackson MI, Johnson LK, Zeng H, Scheett AJ, Uthus EO, 
Schomburg L, Hoeg A, Hoefig CS, Davis CD, Milner JA. Determinants of selenium status in 
healthy adults. Nutr J 2011;10:75.  
38. Lloyd B, Lloyd RS, Clayton BE. Effect of smoking, alcohol, and other factors on the 
selenium status of a healthy population. J Epidemiol Community Health 1983;37(3):213-7. 
39. Fortmann SP, Burda BU, Senger CA, Lin JS, Whitlock EP. Vitamin and Mineral 
Supplements in the Primary Prevention of Cardiovascular Disease and Cancer: An Updated 
Systematic Evidence Review for the U.S. Preventive Services Task Force. Ann Intern Med 
2013.  
40. Michaelis M, Gralla O, Behrends T, Scharpf M, Endermann T, Rijntjes E, Pietschmann 
N, Hollenbach B, Schomburg L. Selenoprotein P in seminal fluid is a novel biomarker of 
sperm quality. Biochem  Biophys Res Commun 2013.  
41. Meplan C, Crosley LK, Nicol F, Beckett GJ, Howie AF, Hill KE, Horgan G, Mathers JC, 
Arthur JR, Hesketh JE. Genetic polymorphisms in the human selenoprotein P gene determine 
the response of selenoprotein markers to selenium supplementation in a gender-specific 
manner (the SELGEN study). FASEB J 2007;21(12):3063-74. 
42. Meplan C, Crosley LK, Nicol F, Horgan GW, Mathers JC, Arthur JR, Hesketh JE. 
Functional effects of a common single-nucleotide polymorphism (GPX4c718t) in the 
glutathione peroxidase 4 gene: interaction with sex. Am J Clin Nutr 2008;87(4):1019-27. 
43. Meplan C, Dragsted LO, Ravn-Haren G, Tjonneland A, Vogel U, Hesketh J. 
Association between polymorphisms in glutathione peroxidase and selenoprotein P genes, 
glutathione peroxidase activity, HRT use and breast cancer risk. PloS one 2013;8(9):e73316. 
44. Meplan C, Nicol F, Burtle BT, Crosley LK, Arthur JR, Mathers JC, Hesketh JE. Relative 
abundance of selenoprotein P isoforms in human plasma depends on genotype, se intake, 
and cancer status. Antioxid Redox Signal 2009;11(11):2631-40.  
45. Meplan C, Hughes DJ, Pardini B, Naccarati A, Soucek P, Vodickova L, Hlavata I, 
Vrana D, Vodicka P, Hesketh JE. Genetic variants in selenoprotein genes increase risk of 
colorectal cancer. Carcinogenesis 2010;31(6):1074-9. 
Page 26 of 32
John Wiley & Sons, Inc.
International Journal of Cancer
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 
26 
 
46. Slattery ML, Lundgreen A, Welbourn B, Corcoran C, Wolff RK. Genetic variation in 
selenoprotein genes, lifestyle, and risk of colon and rectal cancer. PloS one 
2012;7(5):e37312. 
47. Zhou X, Smith AM, Failla ML, Hill KE, Yu Z. Estrogen status alters tissue distribution 
and metabolism of selenium in female rats. J Nutr Biochem 2012;23(6):532-8. 
48. Norat T, Bingham S, Ferrari P, Slimani N, Jenab M, Mazuir M, Overvad K, Olsen A, 
Tjonneland A, Clavel F, Boutron-Ruault MC, Kesse E, et al. Meat, fish, and colorectal cancer 
risk: the European Prospective Investigation into cancer and nutrition. J Natl Cancer Inst 
2005;97(12):906-16. 
49. O'Morain CA, Van Cutsem E, Spicak J, Classen M, Faulds Wood L, Stockbrugger R. 
European initiatives in colorectal cancer screening. Eur J Gastroenterol Hepatol 
2011;23(3):201-3. 
50. Rayman MP, Stranges S. Epidemiology of selenium and type 2 diabetes: Can we 
make sense of it? Free Radic Biol Med 2013. 
 
 
Table Legends 
Table 1. Selected baseline characteristics of incident colon and rectal cancer cases and their 
matched controls, the EPIC study. 
Table 2.  Geometric mean (95% CI) selenium and selenoprotein P concentrations in 
controls by age and other baseline characteristics. 
Table 3. Incidence rate ratios (IRRs) and 95% confidence intervals (95%CI) for CRC and its 
sub-sites by quintiles of serum selenium concentration among all participants and by sex, 
EPIC cohort study, 1992-2003. 
Table 4. Incidence rate ratios (IRRs) and 95% confidence intervals (95%CI) for CRC and its 
sub-sites by quintiles of serum SePP concentration, EPIC cohort study, 1992-2003. 
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Table 1. Selected baseline characteristics of incident colon and rectal cancer cases and their matched controls, the EPIC study  
Characteristic* 
Colon cancer 
 
Rectal cancer  
Cases Controls P-value**  Cases Controls P-value** 
N 598 598 
 
368 368  
Women, % 54.5 54.5 *** 47.3 47.3 *** 
Age at blood collection, yrs 58.9 (7.2) 58.8 (7.3) *** 58.3 (6.9) 58.3 (6.9) *** 
Years between blood collection and 
diagnosis   
3.7 (2.1) 
--  
3.9 (2.1) 
-- 
 
Educational attainment, % 
  
0.396 
  
0.672 
 
Primary  34.0 39.0 
 
32.6 36.1  
 
Technical/professional school 23.9 24.9 
 
27.5 27.7  
 
Secondary 16.2 13.2 
 
13.0 11.7  
 
University degree  17.4 15.4 
 
18.8 19.0  
Smoking status, % 
  
0.436 
  
0.678 
 
Never smoker 39.6 43.5 
 
38.0 40.8  
 
Former smoker 34.0 33.4 
 
32.3 31.8  
 
Current smoker 25.6 22.1 
 
29.1 26.4  
Physical activity, % 
  
0.102 
  
0.677 
 
Inactive  16.2 11.5 
 
15.5 14.7  
 
Moderately inactive 29.9 32.3 
 
28.8 26.6  
 
Moderately active 43.5 43.7 
 
44.3 42.4  
 
Active 9.7 11.5 
 
11.4 14.1  
Among women 
     
 
 
Premenopausal, % 11.7 12.3 0.824 8.6 9.2 0.887 
 
HRT use, % 25.5 23.9 0.553 19.0 26.4 0.127 
 
Oral contraceptive use, % 40.5 43.6 0.396 44.3 51.2 0.318 
BMI, kg/m
2
 26.9 (4.6) 26.3 (3.8) 0.017 26.6 (4.0) 26.4 (3.8) 0.607 
Baseline dietary intakes 
     
 
 
Total energy, kcal/d 2156.4 (753.1) 2134.5 (614.6) 0.543 2226.7 (698.1) 2183.3 (635.8) 0.343 
 
Alcohol, g/d 16.0 (20.5) 15.0 (18.7) 0.291 20.5 (24) 17.6 (21.9) 0.056 
 
Calcium, mg/d 1013.9 (425) 1042.9 (409.8) 0.218 1007.1 (413.4) 1057.2 (430.9) 0.111 
 
Fiber, g/d 22.9 (8.2) 23.9 (8.2) 0.047 23.6 (7.8) 23.7 (7.8) 0.790 
 
Folate, g/d 307.6 (113) 316.1 (112.9) 0.139 316 (110.9) 310.5 (98.5) 0.459 
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Fruit and vegetables, g/d 418.7 (262.9) 455.1 (261.4) 0.007 411.1 (264.2) 411.9 (226.3) 0.964 
 
Fish and shellfish, g/d 34.9 (31.9) 37.9 (34.3) 0.078 36.8 (29.1) 37.7 (33.4) 0.662 
 
Red and processed meat, g/d 91.4 (76.9) 85.6 (51.2) 0.085 100.3 (59) 96.5 (58.1) 0.258 
Baseline serum biomarkers, geometric mean (5
th
-95
th
 percentile)  
 
Selenium, µg/L 80.1 (49.5-118.3) 82.1 (52.1-125.1) 0.097 83.3 (52.9-121.3) 83.6 (53.4-126) 0.816 
 Selenoprotein P, mg/L 4.1 (2.7-6.0) 4.3 (2.9-6.1) 0.008 4.2 (3.0-5.9) 4.3 (2.9-6.0) 0.922 
Abbreviations: HRT=hormone replacement therapy; BMI = body mass index.   
*Data are given as means (SD) unless otherwise specified. Number of missing/unknown: smoking = 17, physical activity = 18, education=52, use of oral contraceptive = 7, HRT 
use=23. Missing values were not excluded from percentage calculations; therefore the sum of percent across subgroups may not add up to 100%.  
** From conditional logistic regression (continuous variables) or chi-square test (categorical variables).  
*** Matching factor. 
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Table 2.  Geometric mean (95% CI) selenium and selenoprotein P concentrations in controls by age and other baseline characteristics. 
 
Characteristic 
Men (N=466) Women (N=500) 
N Selenium, µg/L P* Selenoprotein P, P* N Selenium, µg/L P* Selenoprotein P, P* 
 466  78.3 (75.1-81.7)   4.1 (4.0-4.3)    500 80.8 (77.8-83.9)   4.1 (4.0-4.3)   
Country                     
 Denmark 197 87.2 (84.2-90.3) <0.001 4.6 (4.4-4.7) <0.001 126 93.1 (89.1-97.3) <0.001 4.7 (4.5-4.9) <0.001 
 France -- --  --  25 82.3 (74.6-90.8)  4.0 (3.7-4.4)  
 Germany 62 74.3 (69.8-79.0)  4.1 (3.9-4.4)  35 73.2 (67.4-79.6)  4.1 (3.8-4.4)  
 Greece 13 57.2 (50.0-65.4)  3.2 (2.9-3.6)  8 55.4 (46.5-65.9)  3.3 (2.8-3.8)  
 Italy 48 77.9 (72.7-83.5)  4.2 (3.9-4.4)  67 84.1 (79.2-89.3)  4.3 (4.1-4.5)  
 Spain 47 90.0 (83.8-96.5)  4.5 (4.3-4.8)  48 82.1 (76.5-88.2)  4.4 (4.1-4.6)  
 The Netherlands 13 65.0 (56.9-74.4)  3.6 (3.2-4.1)  98 79.0 (75.2-83.0)  4.1 (3.9-4.3)  
 United Kingdom 86 83.2 (79.0-87.7)  4.2 (4.0-4.4)  93 81.4 (77.4-85.7)  4.0 (3.8-4.1)  
Region**           
 Southern 157 79.8 (76.6-83.1) <0.001 4.3 (4.1-4.4) <0.001 175 81.0 (78.0-84.2) <0.001 4.2 (4.1-4.4) <0.001 
 Central 112 77.4 (73.8-81.2)  4.0 (3.9-4.2)  199 79.0 (76.2-81.9)  4.0 (3.9-4.1)  
 Northern 197 87.2 (84.1-90.4)  4.6 (4.4-4.7)  126 93.1 (89.1-97.4)  4.7 (4.5-4.9)  
Age at blood collection, years          
 <55 125 78.2 (74.2-82.4) 0.566 4.2 (4.0-4.3) 0.290 159 80.9 (76.8-85.2) 0.466 4.1 (3.9-4.2) 0.078 
 55-59 135 78.8 (74.7-83.2)  4.1 (3.9-4.3)  124 79.5 (75.2-84.0)  4.1 (3.9-4.3)  
 60-64 138 80.8 (76.6-85.2)  4.2 (4.0-4.4)  126 81.0 (76.3-85.8)  4.2 (4.0-4.4)  
 ≥65 68 75.5 (69.7-81.8)  3.9 (3.7-4.2)  91 82.8 (77.1-88.8)  4.3 (4.0-4.6)  
BMI, kg/m
2
           
 <25 141 74.8 (71.0-78.9) 0.525 4.0 (3.8-4.2) 0.692 231 79.7 (76.0-83.6) 0.604 4.1 (3.9-4.2) 0.138 
 25-30 259 80.6 (77.4-84.0)  4.2 (4.0-4.3)  200 81.8 (77.8-86.0)  4.2 (4.0-4.4)  
 >30 66 76.6 (71.6-82.0)  4.0 (3.8-4.3)  69 81.3 (75.8-87.2)  4.3 (4.0-4.5)  
Smoking status           
 Never 119 81.4 (77.2-85.8) 0.041 4.1 (3.9-4.3) 0.428 291 80.6 (77.1-84.2) 0.596 4.1 (4.0-4.3) 0.609 
 Former 201 79.0 (75.4-82.8)  4.2 (4.0-4.3)  116 81.7 (77.0-86.7)  4.1 (3.9-4.4)  
 Current 139 75.3 (71.4-79.3)  4.0 (3.9-4.2)  90 78.8 (73.7-84.2)  4.0 (3.8-4.3)  
Physical activity           
 Active 76 78.1 (73.1-83.5) 0.891 4.2 (4.0-4.4) 0.813 47 80.3 (74.0-87.1) 0.347 4.1 (3.8-4.4) 0.307 
 Moderately active 72 79.8 (75.8-84.0)  4.3 (4.1-4.4)  49 80.9 (77.1-84.9)  4.2 (4.0-4.4)  
 Moderately inactive 10 77.7 (73.8-81.8)  4.1 (3.9-4.2)  4 82.0 (77.9-86.4)  4.1 (4.0-4.3)  
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 Inactive 136 77.2 (72.3-82.4)  4.0 (3.8-4.2)  155 76.2 (70.1-82.9)  3.9 (3.6-4.2)  
Alcohol at baseline, g/d           
 None 10 74.3 (63.3-87.1) 0.398 3.8 (3.3-4.3) 0.101 25 79.7 (71.1-89.3) 0.301 4.1 (3.7-4.5) 0.353 
 0.1 - 6 109 75.5 (71.2-80.0)  4.0 (3.8-4.2)  236 80.8 (77.0-84.9)  4.1 (3.9-4.3)  
 6.1-12 79 79.1 (74.3-84.3)  4.1 (3.9-4.3)  100 79.8 (74.9-84.9)  4.2 (4.0-4.4)  
 12.1-24 95 82.4 (77.7-87.4)  4.3 (4.1-4.5)  89 84.2 (78.9-89.9)  4.3 (4.1-4.5)  
 24.1-36 60 76.7 (71.4-82.3)  4.1 (3.9-4.4)  35 84.3 (76.7-92.7)  4.2 (3.9-4.6)  
 >36 113 80.3 (75.8-85.0)  4.2 (4.0-4.4)  15 74.5 (65.0-85.3)  4.0 (3.6-4.5)  
Baseline dietary intakes:          
Total fish and shellfish, g/d          
 None 13 80.4 (69.8-92.6) 0.405 3.7 (3.3-4.2) 0.021 14 80.6 (70.0-92.9) 0.488 3.8 (3.4-4.3) 0.051 
 0.1-15 74 75.0 (70.3-79.9)  4.0 (3.8-4.2)  140 76.3 (71.8-81.1)  4.0 (3.8-4.2)  
 15.1-30 117 76.2 (72.0-80.6)  4.0 (3.8-4.2)  127 82.9 (78.3-87.8)  4.1 (3.9-4.3)  
 30.1-50 125 80.4 (75.9-85.2)  4.1 (3.9-4.3)  106 83.1 (78.1-88.5)  4.3 (4.0-4.5)  
 >50 137 82.9 (78.3-87.8)  4.3 (4.1-4.5)  113 81.7 (77.1-86.5)  4.2 (4.0-4.4)  
Fruits and vegetables, g/d          
 ≤260 150 75.6 (71.4-79.9) 0.121 4.0 (3.8-4.2) 0.137 91 80.3 (75.1-86.0) 0.586 4.0 (3.8-4.3) 0.017 
 260.1-400 116 78.0 (73.5-82.7)  4.1 (3.9-4.3)  129 78.3 (73.9-83.1)  4.0 (3.8-4.2)  
 400.1-560 107 81.0 (76.7-85.6)  4.2 (4.0-4.4)  134 84.7 (80.0-89.7)  4.2 (4.0-4.4)  
 >560 93 79.5 (75.0-84.2)  4.1 (3.9-4.3)  146 80.0 (76.0-84.1)  4.2 (4.0-4.4)  
Red and processed meats, g/d          
 ≤50 69 76.1 (71.1-81.4) 0.140 3.9 (3.6-4.1) 0.011 150 81.8 (77.6-86.2) 0.256 4.2 (4.1-4.4) 0.059 
 50-80 89 79.4 (74.8-84.2)  4.2 (3.9-4.4)  161 81.7 (77.4-86.2)  4.2 (4.0-4.4)  
 80-120 135 77.0 (72.9-81.4)  4.2 (4.0-4.4)  139 79.2 (74.9-83.8)  4.0 (3.8-4.2)  
 >120 173 82.3 (77.8-87.0)  4.3 (4.1-4.5)  50 78.6 (72.6-85.0)  4.0 (3.7-4.3)  
* All P-values are based on a test of linear trend, except P-values for heterogeneity by country, geographical region, sex, smoking status and educational level. 
**Geographical regions:  South = France, Italy, Spain, Greece; Central = UK, the Netherlands, Germany; Northern = Denmark. 
All analyses were adjusted for study center, except analysis for country/region. 
Number of missing/unknown among controls: smoking = 10, physical activity = 14. 
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Table 3. Incidence rate ratios (IRRs) and 95% confidence intervals (95% CI) for CRC and its sub-sites by quintiles of serum selenium concentration among all 
participants and by sex, EPIC cohort study, 1992-2003. 
  
    
All participants   Men Women  
Cancer site  
Se, µg/L 
No. of 
ca/co 
Matching 
factors* 
Multivariable 
adjusted† No. of 
ca/co 
Matching 
factors* 
Multivariable 
adjusted† No. of 
ca/co 
Matching 
factors* 
Multivariable 
adjusted† 
P 
heterogeneity 
by sex† IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) 
Colorectal cancer                  
  <67.7 203/193 ref. ref. 86/96 ref. ref. 117/97 ref. ref. 0.105
&
 
  67.7 – 78.3 201/193 0.99(0.75-1.30) 0.98(0.74-1.30) 86/91 1.06(0.70-1.59) 0.94(0.60-1.45) 115/102 0.91(0.63-1.33) 0.95(0.64-1.41)  
  78.31-88.2 185/193 0.90(0.67-1.20) 0.93(0.69-1.26) 89/89 1.14(0.75-1.73) 1.14(0.73-1.78) 96/104 0.73(0.48-1.09) 0.84(0.54-1.30)  
  88.3-100.6 195/193 0.95(0.71-1.27) 0.96(0.71-1.31) 111/102 1.25(0.83-1.89) 1.25(0.80-1.97) 84/91 0.73(0.48-1.11) 0.75(0.48-1.17)  
  >100.6 182/194 0.87(0.64-1.18) 0.88(0.64-1.21) 94/88 1.23(0.79-1.91) 1.18(0.73-1.90) 88/106 0.63(0.41-0.97) 0.64(0.40-1.01)  
  Ptrend   0.381 0.458   0.246 0.262   0.020 0.032  
Per 25 µg/L     0.91(0.82-1.02) 0.92(0.82-1.03)   1.03(0.88-1.2) 1.02(0.86-1.22)   0.81(0.70-0.95) 0.83(0.70-0.97)  
Colon cancer                    
  <67.7 142/123 ref. ref. 58/58 ref. ref. 84/65 ref. ref. 0.613
&
 
  67.7 – 78.3 130/116 0.96(0.68-1.35) 0.94(0.66-1.35) 55/49 1.12(0.66-1.89) 1.01(0.56-1.81) 75/67 0.85(0.54-1.34) 0.86(0.52-1.41)  
  78.31-88.2 114/128 0.75(0.52-1.07) 0.75(0.51-1.10) 53/54 0.97(0.57-1.65) 0.96(0.53-1.72) 61/74 0.60(0.37-0.99) 0.65(0.38-1.12)  
  88.3-100.6 99/116 0.71(0.48-1.04) 0.73(0.49-1.10) 54/62 0.85(0.49-1.48) 0.86(0.46-1.59) 45/54 0.62(0.37-1.05) 0.62(0.35-1.12)  
  >100.6 113/115 0.82(0.55-1.20) 0.81(0.54-1.23) 52/49 1.05(0.59-1.87) 1.11(0.58-2.12) 61/66 0.66(0.39-1.13) 0.61(0.34-1.09)  
  Ptrend   0.103 0.154   0.789 0.963   0.052 0.045  
Per 25 µg/L     0.88(0.76-1.02) 0.90(0.77-1.05) 
 
0.94(0.76-1.16) 0.97(0.77-1.23) 
 
0.84 (0.69-1.02) 0.84 (0.68-1.05) 
 Rectal cancer                    
  <67.7 61/70 ref. ref. 28/38 ref. ref. 33/32 ref. ref.  
  67.7 – 78.3 71/77 1.04(0.65-1.66) 1.24(0.74-2.08) 31/42 0.94(0.48-1.84) 1.03(0.44-2.39) 40/35 1.10(0.56-2.15) 1.52(0.70-3.29) 0.273
&
 
  78.31-88.2 71/65 1.28(0.78-2.10) 1.49(0.86-2.60) 36/35 1.50(0.75-2.96) 1.41(0.59-3.37) 35/30 1.09(0.52-2.28) 1.68(0.67-4.25)  
  88.3-100.6 96/77 1.46(0.91-2.33) 1.61(0.95-2.72) 57/40 2.06(1.08-3.94) 2.39(1.01-5.67) 39/37 0.99(0.49-1.99) 1.26(0.55-2.87)  
  >100.6 69/79 1.01(0.61-1.67) 1.09(0.63-1.89) 42/39 1.53(0.76-3.06) 1.32(0.55-3.19) 27/40 0.62(0.29-1.31) 0.76(0.32-1.80)  
  Ptrend   0.516 0.568   0.039 0.170   0.199 0.271  
Per 25 µg/L     0.95(0.80-1.12) 0.93(0.78-1.11)   1.16(0.91-1.48) 1.14(0.84-1.55)   0.78(0.61-1.0) 0.74(0.57-0.98)  
P heterogeneity by sub-site†  0.097
&
   0.219
&
   0.474
&
  
Abbreviations: Se = selenium; No = Number; Ca = Cases; Co = controls; IRR = incidence rate ratio; CI = confidence interval; ref = reference. 
*Model based on matching factors only. 
†Model based on matching factors plus further adjustments for smoking status/duration/intensity, body mass index, total physical activity, education level, total dietary energy 
consumption, and intake of total calcium, fruits and vegetables, red and processed meats, and alcohol. 
& 
P-value for heterogeneity for serum selenium concentration categorized into quintiles.
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Table 4. Incidence rate ratios (IRRs) and 95% confidence intervals (95% CI) for CRC and its sub-sites by quintiles of serum SePP concentration, EPIC cohort study, 1992-
2003. 
Cancer site    
SePP, mg/L 
 
All participants Men               Women 
 
 
No. of 
ca/co 
Matching factors* 
Multivariable 
adjusted† No. of 
ca/co 
Matching factors* 
Multivariable 
adjusted† No. of 
ca/co 
Matching factors*
Multivariable 
adjusted† 
P 
heterogeneity 
by sex† IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) 
Colorectal cancer                   
 
< 3.617 236/193 ref. ref. 96/84 ref. ref. 140/109 ref. ref. 0.230
&
 
 
3.618 – 4.113 175/193 0.71(0.53-0.95) 0.72(0.53-0.97) 79/91 0.74(0.48-1.14) 0.67(0.42-1.07) 96/102 0.68(0.47-1.00) 0.71(0.47-1.07)  
 
4.114 – 4.558 219/193 0.91(0.69-1.20) 0.89(0.67-1.20) 100/92 0.95(0.63-1.43) 0.81(0.51-1.29) 119/101 0.88(0.61-1.28) 0.94(0.62-1.41)  
 
4.589 – 5.150 168/193 0.67(0.50-0.91) 0.69(0.51-0.94) 97/99 0.84(0.55-1.28) 0.82(0.52-1.29) 71/94 0.53(0.35-0.81) 0.56(0.35-0.89)  
> 5.151 168/194 0.62(0.44-0.86) 0.60(0.42-0.85) 94/100 0.78(0.49-1.24) 0.73(0.43-1.22) 74/94 0.48(0.30-0.78) 0.46(0.28-0.78)  
 
Ptrend 0.008 0.009 0.501 0.485 
 
0.002 0.004  
Per 0.806 mg/L   
 
0.90(0.83-0.98) 0.89(0.82-0.98) 0.99(0.88-1.12) 0.98(0.86-1.12) 
 
0.82(0.73-0.93) 0.82(0.72-0.94)  
Colon cancer 
 
       
 
 
< 3.617 154/116 ref. ref. 57/47 ref. ref. 97/69 ref. ref. 0.421
&
 
 
3.618 – 4.113 114/117 0.69(0.48-0.99) 0.71(0.48-1.04) 46/49 0.75(0.43-1.32) 0.70(0.38-1.31) 68/68 0.63(0.39-1.02) 0.73(0.43-1.24)  
 
4.114 – 4.558 123/117 0.77(0.54-1.10) 0.76(0.52-1.12) 54/53 0.82(0.47-1.43) 0.82(0.44-1.56) 69/64 0.74(0.46-1.18) 0.85(0.50-1.44)  
 
4.589 – 5.150 105/124 0.58(0.40-0.85) 0.63(0.42-0.94) 61/59 0.82(0.47-1.42) 0.89(0.48-1.65) 44/65 0.42(0.25-0.71) 0.48(0.27-0.87)  
> 5.151 102/124 0.52(0.34-0.79) 0.49(0.31-0.76) 54/64 0.62(0.33-1.14) 0.53(0.26-1.06) 48/60 0.45(0.25-0.80) 0.44(0.23-0.84)  
 
Ptrend 0.002 0.003 0.232 0.232 
 
0.002 0.008  
Per 0.806 mg/L   
 
0.86(0.77-0.96) 0.85(0.75-0.95) 0.92(0.79-1.08) 0.89(0.74-1.07) 
 
0.81(0.70-0.94) 0.82(0.69-0.96)  
Rectal cancer 
   
     
 
 
< 3.617 82/77 ref. ref. 39/37 ref. ref. 43/40 ref. ref. 0.657
&
 
 
3.618 – 4.113 61/76 0.72(0.45-1.15) 0.71(0.43-1.18) 33/42 0.70(0.35-1.37) 0.61(0.26-1.44) 28/34 0.75(0.39-1.43) 0.66(0.31-1.41)  
 
4.114 – 4.558 96/76 1.21(0.78-1.88) 1.27(0.78-2.06) 46/39 1.16(0.62-2.18) 1.10(0.49-2.47) 50/37 1.26(0.68-2.33) 1.28(0.60-2.74)  
 
4.589 – 5.150 63/69 0.86(0.53-1.38) 0.93(0.55-1.57) 36/40 0.83(0.43-1.59) 0.89(0.40-1.96) 27/29 0.88(0.42-1.84) 0.82(0.34-1.98)  
> 5.151 66/70 0.85(0.49-1.47) 0.80(0.43-1.48) 40/36 1.10(0.53-2.27) 0.95(0.37-2.43) 26/34 0.55(0.23-1.33) 0.53(0.19-1.48)  
 
Ptrend 0.784 0.806 0.721 0.805 
 
0.394 0.386  
Per 0.806 mg/L     0.98(0.85-1.13) 0.96(0.82-1.13)   1.09(0.90-1.31) 1.08(0.85-1.37)   0.84(0.67-1.06) 0.82(0.63-1.08)  
P heterogeneity by sub-site†  0.231
&
   0.632
&
   0.710
&
  
Abbreviations: SePP = selenoprotein P; No = Number; Ca = Cases; Co = controls; IRR = incidence rate ratio; CI = confidence interval; ref = reference.  
*Model based on matching factors only. 
†Model based on matching factors plus further adjustments for smoking status/duration/intensity, body mass index, total physical activity, education level, total dietary energy consumption, and 
intake of total calcium, fruits and vegetables, red and processed meats, and alcohol. 
& 
P-value for heterogeneity for serum SePP concentration categorized into quintiles.
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